Potential use of exenatide for the treatment of obesity

New Drug Targets for the Treatment of Obesity

(2011) A G Powell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of Exenatide on Measures of  -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes

(2011) M. C. Bunck et al.   DIABETES CARE

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly in type 2 diabetes mellitus

(2011) Lindsay A Bischoff et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The future of obesity medicine: where do we go from here?

(2011) Suzanne M. Wright et al.   Nature Reviews Endocrinology

The Pharmacological Treatment and Management of Obesity

(2011) Syed Sufyan Hussain et al.   POSTGRADUATE MEDICINE

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years

(2011) Kristin Taylor et al.   BMC Endocrine Disorders

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

(2010) Caroline M. Apovian et al.   AMERICAN JOURNAL OF MEDICINE

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

(2010) M. C. Bunck et al.   DIABETES CARE

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Effect of Exenatide on Fat Deposition and a Metabolic Profile in Patients with Metabolic Syndrome

(2010) Manuel González-Ortiz et al.   Metabolic Syndrome and Related Disorders

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

(2009) Richard Bergenstal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy

(2009) Eric Ravussin et al.   Obesity

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

(2008) Karen Elkind-Hirsch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET

Nonsurgical Management of Obesity in Adults

(2008) Robert H. Eckel   NEW ENGLAND JOURNAL OF MEDICINE

Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet

(2008) Iris Shai et al.   NEW ENGLAND JOURNAL OF MEDICINE